Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer
OBJECTIVES:
- Determine bone mineral density (BMD) in patients with clinically significant early
stage prostate cancer.
- Determine whether patients who have a higher level of BMD and have had a radical
prostatectomy for cure are less likely to have an early relapse (i.e., less than 3
years) than those patients with a low level of BMD.
OUTLINE: This is a case-controlled study followed by a prospective, longitudinal, cohort
study.
Patients undergo bone mineral density (BMD) measurements by dual-energy x-ray absorptiometry
with a densitometer. Posteroanterior measurements of the total hip are also recorded.
Patients also undergo blood collection to examine markers that provide evidence of systemic
disease.
Patients are followed every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Observational
Observational Model: Case Control, Time Perspective: Prospective
Bone mineral density
DXA scan will be done after patient signs consent and eligibilty is confirmed
Baseline
No
Stephen W. Marcella, MD, MPH
Principal Investigator
Cancer Institute of New Jersey
United States: Federal Government
CDR0000539677
NCT00176579
June 2003
July 2008
Name | Location |
---|---|
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | New Brunswick, New Jersey 08903 |